• Other

    Roche to acquire liver drug developer 89bio for up to $3.5 billion – Reuters

    AnyFans Posted on

    By Ludwig Burger

    Copyright reuters

    Roche to acquire liver drug developer 89bio for up to $3.5 billion - Reuters

    SummaryCompaniesRoche targets liver disease treatments with acquisitionDeal includes $14.50 a share, potential milestone payments up to $6.00 a shareRoche flags potential to treat obesity-related conditions

    FRANKFURT, Sept 18 (Reuters) – Roche (ROG.S), opens new tab has agreed to buy U.S. biotech firm 89bio (ETNB.O), opens new tab for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs.

    The deal would help Roche grow in a field related to the booming weight-loss market, where the company has recently made major inroads.

    In a statement on Thursday, Roche said the deal was worth about $2.4 billion, or up to $3.5 billion when including a non-tradeable contingent value right.

    Advertisement · Scroll to continue

    The target company’s leading drug pegozafermin, part of a class known as FGF21 analogues, is in late stages of development to treat fatty liver, formally known as metabolic dysfunction-associated steatohepatitis, including advanced stages.

    Roche said it would tender to buy all 89bio common stock for $14.50 a share in cash and a contingent value right to receive certain milestone payments of up to $6.00 a share.

    Shares of the San Francisco-based 89bio rose about 86% to $15.02 in premarket trading.

    Roche said the acquisition underscored its dedication to advancing therapies in cardiovascular, renal, and metabolic diseases, especially for those overweight or battling obesity and related challenges such as fatty liver, also known as MASH.

    Advertisement · Scroll to continue

    “It’s a very nice complement in terms of being able to treat another very common comorbid condition with obesity,” Teresa Graham, the head of Roche’s pharmaceutical division, told Reuters.

    INTENSE DEAL ACTIVITY

    This year, the company acquired rights to an obesity therapy developed by Denmark’s Zealand Pharma (ZELA.CO), opens new tab in a deal worth up to $5.3 billion, and in late 2023, it struck a deal to buy weight-loss drug developer Carmot for $2.7 billion upfront.

    Other FGF21 analogues have attracted intense research and deal activity. In May, GSK (GSK.L), opens new tab agreed to buy a liver disease drug for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals.

    For its part, Akero Therapeutics (AKRO.O), opens new tab said early this year its drug candidate helped reverse some liver damage in a mid-stage trial, prompting its shares to more than double.

    Ad Break Coming Up

    NEXT StayNext

    OffEnglish

    180p288p360p480p540p576p720pHD1080pHDAuto (180p)

    About ConnatixV2047461311
    About ConnatixV2047461311

    Continue watchingafter the adVisit Advertiser websiteGO TO PAGE

    The Roche-89bio deal underscores the escalating strategic value of differentiated MASH assets, H.C. Wainwright analysts said in a note.

    When asked how 89bio’s compound compares to rival drug candidates, Roche’s Graham said, “We believe that this has the potential to have best-in-disease efficacy, as well as an attractive convenience profile.”

    Roche would consider testing pegozafermin in combination with weight-loss drug candidates, in addition to its mono-therapy trial programme, she added.

    Drugmakers Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab, who lead the booming market for weight-loss treatments with their GLP-1 treatments, are testing those drugs as well for a wider role against the liver disease.

    Reporting by Ludwig Burger, additional reporting by Sneha S K in Bengaluru; Editing by Jan Harvey and Clarence Fernandez

    Purchase Licensing Rights

    You Might Also Like